Skip to main content

Table 3 Clinical outcomes

From: The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles

Varibales

uFSH

(n = 764)

rFSH-alfa

(n = 314)

P

CLBR

329 (43.1%)

168 (53.5%)

0.002

Time to first live birth (days)

404.0 (357.0–496.0)

392.0 (356.0–452.8)

0.471

Fresh embryo transfer, n

201 (26.3%)

110 (35.0%)

0.005

 Pregnancy, n/N (%)

68/201 (33.8%)

36/110 (32.7%)

0.844

 Abortion

8/68 (11.8%)

4/36 (11.1%)

0.921

 Live birth

54/201 (26.9%)

28/110 (25.5%)

0.787

 Multiple birth

5/201 (2.5%)

9/110 (8.2%)

0.021

Frozen embryo transfer cycles

706

354

 

 Pregnancy, n/N (%)

344/706 (48.7%)

169/354 (47.7%)

0.762

 Abortion

56/344 (16.3%)

23/169 (13.6%)

0.431

 Live birth

276/706 (39.1%)

142/354 (40.1%)

0.749

 Multiple birth

53/706 (7.5%)

28/354 (7.9%)

0.816

  1. CLBR Cumulative live birth rate; FSH follicle-stimulating hormone